公开(公告)号：US20240350680A1

公开(公告)日：2024-10-24

申请号：US18440783

申请日：2024-02-13

申请人： NOVARTIS AG

发明人： Matthias EDER ,  Klaus KOPKA ,  Martin SCHÄFER ,  Ulrike BAUDER-WÜST ,  Michael EISENHUT ,  Walter MIER ,  Martina BENESOVA

IPC分类号： A61K51/04 ,  C07B59/00 ,  C07D257/02 ,  C07D295/145

CPC分类号： A61K51/0482 ,  A61K51/0402 ,  A61K51/0497 ,  C07B59/002 ,  C07D257/02 ,  C07D295/145

摘要： The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

公开(公告)号：US20240343749A1

公开(公告)日：2024-10-17

申请号：US18438523

申请日：2024-02-12

申请人： UNIVERSAL DISPLAY CORPORATION

发明人： Alexey Borisovich DYATKIN ,  Jui-Yi TSAI ,  Wei-Chun SHIH ,  Elena SHEINA ,  Pierre-Luc T. BOUDREAULT

IPC分类号： C07F15/00 ,  C07B59/00 ,  H10K85/30 ,  H10K85/40 ,  H10K85/60

CPC分类号： C07F15/0033 ,  C07B59/004 ,  C07F15/0086 ,  H10K85/342 ,  H10K85/346 ,  H10K85/40 ,  H10K85/615 ,  H10K85/654 ,  H10K85/6574 ,  H10K85/658 ,  C07B2200/05

摘要： Provided are organometallic compounds wherein a boron containing group bridges two monocyclic or fused polycyclic ring systems each independently comprised of one or more 5-membered or 6-membered rings. Also provided are formulations comprising these organometallic compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these organometallic compounds.

公开(公告)号：US12116355B2

公开(公告)日：2024-10-15

申请号：US17340201

申请日：2021-06-07

申请人： H. Lundbeck A/S

发明人： Morten Jorgensen ,  Peter Hongaard Andersen ,  Klaus Gjervig Jensen

IPC分类号： C07D295/073 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/554 ,  C07B59/00 ,  C07C45/61 ,  C07C45/67 ,  C07D241/04

CPC分类号： C07D295/073 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/554 ,  C07B59/002 ,  C07C45/61 ,  C07C45/67 ,  C07D241/04 ,  C07B2200/05

摘要： The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.

公开(公告)号：US20240336644A1

公开(公告)日：2024-10-10

申请号：US18584263

申请日：2024-02-22

申请人： ZHEJIANG UNIVERSITY OF TECHNLOLOGY ,  ZHEJIANG HUAXIAN PHOTOELECTRICITY TECHNOLOGY CO., LTD

发明人： Guijie LI ,  Kewei XU ,  Jianbing ZHENG ,  Yuanbin SHE ,  Disheng HUANG

IPC分类号： C07F15/00 ,  C07B59/00 ,  H10K85/30 ,  H10K85/40 ,  H10K85/60

CPC分类号： C07F15/0086 ,  C07B59/004 ,  H10K85/346 ,  H10K85/40 ,  H10K85/615 ,  H10K85/6574 ,  C07B2200/05 ,  C07B2200/09

摘要： The disclosure relates to the technical field of preparation of circularly polarized luminescence materials, in particular to a central chirality induced helical chiral tetradentate cyclometalated platinum (II) complex, an electronic device and application thereof. The central chirality induced helical chiral tetradentate cyclometalated platinum (II) complex provided in the disclosure has a general structure as shown in formula (I) or (I′) in which (I) and (I′) are enantiomers to each other:




Helical chiral metal complex molecules can autonomously induce a whole tetradentate ligand to coordinate with metal ions in a less sterically hindered manner by means of a central chiral fragment La in the tetradentate ligand, to form an optically pure helical chiral metal complex-based circularly polarized luminescence material, without need for chiral resolution. Moreover, the material has high chemical stability and thermal stability, and has important applications in circularly polarized luminescence elements.

公开(公告)号：US20240334814A1

公开(公告)日：2024-10-03

申请号：US18574016

申请日：2022-06-17

申请人： IDEMITSU KOSAN Co.,LTD.

发明人： Tetsuya MASUDA ,  Hiroyuki IWABUCHI ,  Masato NAKAMURA ,  Yoshinao SHIRASAKI ,  Satomi TASAKI ,  Hiroaki TOYOSHIMA

IPC分类号： H10K85/60 ,  C07B59/00 ,  H10K71/16 ,  H10K85/20 ,  H10K85/40

CPC分类号： H10K85/622 ,  C07B59/004 ,  H10K71/164 ,  H10K85/20 ,  H10K85/40 ,  H10K85/623 ,  H10K85/633 ,  H10K85/653 ,  H10K85/654 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576 ,  H10K85/658 ,  C07B2200/05

摘要： A mixed powder comprising a first compound and a second compound, wherein the first compound has the fused ring structure having the most rings and having three or more rings, in fused ring structures included therein, and the second compound has the fused ring structure having the most rings and having 5 or more rings, in fused ring structures included therein, and the fused ring structure having the most rings thereof has more rings than that of the first compound.

公开(公告)号：US12084452B2

公开(公告)日：2024-09-10

申请号：US17902618

申请日：2022-09-02

申请人： BRISTOL-MYERS SQUIBB COMPANY ,  UNIVERSITÉ DE MONTRÉAL

发明人： Jacques Banville ,  Roger Rémillard ,  Edward H. Ruediger ,  Daniel H. Deon ,  Marc Gagnon ,  Laurence Dubé ,  Julia Guy ,  Eldon Scott Priestley ,  Shoshana L. Posy ,  Brad D. Maxwell ,  Pancras C. Wong ,  R. Michael Lawrence ,  Michael M. Miller

IPC分类号： C07D487/04 ,  A61K31/433 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/553 ,  A61K45/06 ,  A61K51/04 ,  C07B59/00 ,  C07D513/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K31/433 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/553 ,  A61K45/06 ,  A61K51/0453 ,  C07B59/002 ,  C07D513/04 ,  C07D519/00 ,  C07B2200/05

摘要： The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

公开(公告)号：US20240294455A1

公开(公告)日：2024-09-05

申请号：US18571275

申请日：2022-06-16

申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E. V.

发明人： Stefan GLÖGGLER ,  Sergey KORCHAK ,  Anil P. JATAP ,  Philip SAUL ,  Denis MOLL

IPC分类号： C07C67/31 ,  C07B59/00 ,  C07C67/307 ,  C07C67/317 ,  C07C69/63 ,  C07C69/732 ,  C07C201/12 ,  C07C205/34 ,  C07C227/18 ,  C07C229/08

CPC分类号： C07C67/31 ,  C07B59/001 ,  C07C67/307 ,  C07C67/317 ,  C07C69/63 ,  C07C69/732 ,  C07C201/12 ,  C07C205/34 ,  C07C227/18 ,  C07C229/08 ,  C07B2200/05

摘要： The present invention relates to a method for preparing a compound suitable for signal enhanced magnetic resonance imaging comprising the steps of vinylating a mono-, di- or tricarboxylic acid comprising a moiety -Q-Z with Q being O or N and Z being a protecting group by using vinyl acetate, cleaving Z, and if Z has not already been converted into an alcohol upon cleavage, converting Q into an alcohol either by using nitrite or by converting Q into bromine followed by hydrolysis yielding a vinyl hydroxy ester. The compounds used may be partly or fully deuterated. Furthermore, the present invention relates to a vinyl hydroxy ester as well as an intermediate of its synthesis, wherein the vinyl moiety of the vinyl hydroxy ester and of the intermediate is partly or fully deuterated.

公开(公告)号：US20240294453A1

公开(公告)日：2024-09-05

申请号：US18445729

申请日：2024-01-02

申请人： Jeffrey Alan McKinney

发明人： Jeffrey Alan McKinney

IPC分类号： C07C39/23 ,  C07B59/00

CPC分类号： C07C39/23 ,  C07B59/001 ,  C07B2200/05 ,  C07C2601/16

摘要： The present invention is generally directed to deuterated agonists and their methods of use. It is more specifically directed to deuterated alpha-7 nicotinic receptor agonists and their methods of use. In one aspect, the present invention involves compounds of the structure 1-34 as shown in FIGS. 1-4. In another aspect, the present invention involves the treatment of a disorder with a compound of the structure 1-34 as shown in FIGS. 1-4.

公开(公告)号：US12064491B2

公开(公告)日：2024-08-20

申请号：US17383577

申请日：2021-07-23

申请人： Advanced Accelerator Applications International SA

发明人： Theodosia Maina-Nock ,  Berthold Artur Nock ,  Marion de Jong Hendriks

IPC分类号： A61K51/08 ,  C07B59/00

CPC分类号： A61K51/088 ,  A61K51/08 ,  C07B59/008

摘要： The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.

公开(公告)号：US12064490B2

公开(公告)日：2024-08-20

申请号：US17383567

申请日：2021-07-23

申请人： Advanced Accelerator Applications International SA

发明人： Theodosia Maina-Nock ,  Berthold Artur Nock ,  Marion de Jong Hendriks

IPC分类号： A61K51/08 ,  C07B59/00

CPC分类号： A61K51/088 ,  A61K51/08 ,  C07B59/008

摘要： The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.